A novel targeting modality to enhance adenoviral replication by vitamin D3 in androgen-independent human prostate cancer cells and tumors

Cancer Research

Volumn 62, Issue 11, 2002, Pages 3084-3092

  Hsieh, Chia Ling ^a,b   Zhau, Haiyen E ^a,b   Chung, Leland W K ^a,b   Yang, Ling ^b   Miao, Li ^b   Yeung, Fang ^b   Kao, Chinghai ^c   Yang, Hua ^d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c Indiana Cancer Pavilion   (United States)

^d JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; COLECALCIFEROL; DNA; MESSENGER RNA; OSTEOCALCIN; PROSTATE SPECIFIC ANTIGEN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CANCER GRAFT; CANCER INHIBITION; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TATA BOX; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ADENOVIRUS E1B PROTEINS; CELL DIVISION; CHOLECALCIFEROL; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; OSTEOCALCIN; PROSTATIC NEOPLASMS; RNA, MESSENGER; UP-REGULATION; VIRUS REPLICATION;

EID: 0036606008     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin
2. Strategies to adapt adenoviral vectors for targeted delivery
3. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection
4. Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein
5. Targeting of adenoviral vectors through a bispecific single-chain antibody
6. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies
7. Delivery systems intended for in vivo gene therapy of cancer: Targeting and replication competent viral vectors
8. Transcriptional targeting of replication-defective adenovirus transgene expression to smooth muscle cells in vivo
9. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells
10. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma
11. Glioma/glioblastoma-specific adenoviral gene expression using the nestin gene regulator
12. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
13. Adenovirus E1A under the control of heterologous promoters: Wide variation in E1A expression levels has little effect on virus replication
14. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts
15. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy
16. Creation of a new transgene cloning site near the right ITR of Ad5 results in reduced enhancer interference with tissue-specific and regulatable promoters
17. The human osteocalcin promoter directs bone-specific vitamin D-regulatable gene expression in transgenic mice
18. A Conditional replication-competent adenoviral vector. Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis
19. Human prostate cancer progression models and therapeutic intervention
20. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis
21. Regulated expression of the bone-specific osteocalcin gene by vitamins and hormones
22. 1,25-Dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene
23. Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells
24. Isolation and characterization of insertion mutants in E 1A of adenovirus type 5
25. Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors
26. Methods for construction of adenovirus vectors
27. Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells
28. Chemogene therapy: Osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model
29. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
30. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts
31. Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion
32. 3 actions in LNCaP human prostate cancer cells are androgen-dependent
33. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised Phase II trial
34. Regulation of human osteocalcin (hOC) promoter in hormone-independent human prostate cancer cells
35. Targeted disruption of Cbfal results in a complete lack of bone formation owing to maturational arrest of osteoblasts
36. Cbfal, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development
37. Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia
38. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system
39. Peehl prostate cancer
40. The role of vitamin D in prostate cancer
41. 3 receptors and actions in human prostate cancer cell lines
42. Vitamin D in the prevention and treatment of prostate cancer
43. 3 analogues